Grant: Discovery Grants Program - Individual
McGill University
$31,000.00
Development of molecular tools for bifidobacterium species
FY 2011-12
Summary
Probiotic and prebiotic products as ""quality of life and managing biological resources"" are on the market in the forms of milk based drinks, yogurts and capsules. Intake of probiotic bacteria is associated with beneficial health benefits to the human and animal hosts, but current understanding of how the bacteria actually illicit these effects is not very good. Although the genetics and molecular tools of more common dairy lactic bacteria like Lactococcus and Lactobacillus exist, knowledge is lacking behind with closely related Bifidobacterium genus, which is phylogenetically and physiologically (bifidus shunt) distinct. After the molecular tools and mechanisms are elucidated, a more rational approach to the therapeutic use of probiotics could be possible. The current focus of my research program is centered on the hypothesis that one can study fundamental scientific knowledge and improve the performance of probiotic strain by genetic manipulation of its expression of certain proteins. As genetic tools become available for bifidobacteria, more work can be done on understanding their physiology and metabolic activities important for survival in food as well as for understanding their beneficial effects in the gastrointestinal system. The short term objectives are to (1) develop food grade cloning and expression systems, (2) construct new over-expression systems for production of a heterologous protein like bile salt hydrolase (BSH) to validate BSH hypothesis for cholesterol lowering effect of Bifidoabcterium lactis strains (BSH mutant, native and over-expressed) in hens and mice models, and 3) demonstrate the hypothesis that one can improve the performance of probiotic strains by cloning the genes of interest in the respective BSH negative mutants. An air and acid tolerant industrial strain, Bifidobacterium lactis clearly identified as probiotic traits that currently used in probiotic yogurts and this presents a challenge as very little genetic expression work has been done. The concept of developing an innovative Bifidobacterium food-grade vector and expression system to advance our understanding of the metabolic activity, gene function, and expression is a novelty that will be useful for researcher and industries to evaluate the probiotic effects.
Program
Discovery Grants Program - Individual
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
23038-2009
Name nom
Lee, Byong
Department département
Microbiology and Immunology
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2009
Award amount
31000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
3
Committee name en
Plant Biology & Food Science
Committee name fr
Biol vég/sc alimentaire
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5201
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Bacteriology
Research subject fr
Bactériologie
Partie
3
Nb partie
5
Application title
Development of molecular tools for bifidobacterium species
Keyword
NSERC
Application summary
Probiotic and prebiotic products as ""quality of life and managing biological resources"" are on the market in the forms of milk based drinks, yogurts and capsules. Intake of probiotic bacteria is associated with beneficial health benefits to the human and animal hosts, but current understanding of how the bacteria actually illicit these effects is not very good. Although the genetics and molecular tools of more common dairy lactic bacteria like Lactococcus and Lactobacillus exist, knowledge is lacking behind with closely related Bifidobacterium genus, which is phylogenetically and physiologically (bifidus shunt) distinct. After the molecular tools and mechanisms are elucidated, a more rational approach to the therapeutic use of probiotics could be possible. The current focus of my research program is centered on the hypothesis that one can study fundamental scientific knowledge and improve the performance of probiotic strain by genetic manipulation of its expression of certain proteins. As genetic tools become available for bifidobacteria, more work can be done on understanding their physiology and metabolic activities important for survival in food as well as for understanding their beneficial effects in the gastrointestinal system. The short term objectives are to (1) develop food grade cloning and expression systems, (2) construct new over-expression systems for production of a heterologous protein like bile salt hydrolase (BSH) to validate BSH hypothesis for cholesterol lowering effect of Bifidoabcterium lactis strains (BSH mutant, native and over-expressed) in hens and mice models, and 3) demonstrate the hypothesis that one can improve the performance of probiotic strains by cloning the genes of interest in the respective BSH negative mutants. An air and acid tolerant industrial strain, Bifidobacterium lactis clearly identified as probiotic traits that currently used in probiotic yogurts and this presents a challenge as very little genetic expression work has been done. The concept of developing an innovative Bifidobacterium food-grade vector and expression system to advance our understanding of the metabolic activity, gene function, and expression is a novelty that will be useful for researcher and industries to evaluate the probiotic effects.